Inflammation & Prognosis in Decompensated Heart Failure

炎

基本信息

批准号：
7371004
负责人：
GARY M FELKER
金额：
$ 15.11万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-04-01 至 2010-03-31
项目状态：
已结题

项目摘要

Decompensated heart failure (DHF) is among the most common indications for hospitalization in the United States, and continues to increase in incidence with the increasing prevalence of heart failure and the aging of the population. Despite the substantial impact of this clinical syndrome, the ability to prospectively risk stratify patients DHF lags far behind that of other comparable cardiovascular disorders. Inflammation has been shown to play an important role in chronic heart failure, but its importance in DHF is unknown. The broad objectives of this proposal focus on defining optimal risk stratification strategies in DHF and on integrating measures of inflammation with traditional clinical data in order to predict future adverse events. Additionally, the project will seek to define the response of serologic markers of inflammation to current therapies and the relationship of that response to subsequent patient outcomes. These aims will be accomplished through a prospective cohort study of patients hospitalized with DHF. Successful completion of these aims will contribute to accurate risk stratification of patients with DHF and to the understanding of the role of inflammation in the transition from a compensated to decompensated clinical syndrome. This research will form the core of a 5-year career development plan for Dr. Michael Felker under the mentorship of Dr. Christopher O'Connor, a nationally recognized expert in patient oriented research in heart failure. They propose a career development plan that combines didactic training in research methodology, active collaboration with basic investigators, and ongoing clinical research experience within the unique research environment of the Duke Clinical Research Institute. In conjunction with carefully selected collaborators, this career development plan will foster Dr. Felker's development into an established independent clinical investigator with expertise in both complex clinical research methodology and the role of inflammation in the pathophysiology of heart failure.

不足的心力衰竭（DHF）是美国住院治疗的最常见迹象之一，随着心力衰竭患病率的增加和人群的衰老，发病率不断增加。尽管该临床综合征产生了重大影响，但前瞻性风险将患者分类的能力远远落后于其他可比的心血管疾病。炎症已被证明在慢性心力衰竭中起着重要作用，但其在DHF中的重要性尚不清楚。该提案的广泛目的集中在定义DHF中的最佳风险分层策略以及将炎症的度量与传统临床数据相结合，以预测未来的不良事件。此外，该项目将寻求定义炎症的血清学标记对当前疗法的反应以及该反应与随后的患者预后的关系。这些目标将通过对住院DHF住院的患者的前瞻性队列研究来实现。这些目标的成功完成将有助于对DHF患者的准确风险分层，并了解炎症在从补偿到代偿型临床综合征过渡中的过渡中的作用。这项研究将构成迈克尔·费尔克（Michael Felker）博士在克里斯托弗·奥康纳（Christopher O'Connor）的指导下为迈克尔·费尔克（Michael Felker）博士进行的5年职业发展计划的核心。他们提出了一项职业发展计划，该计划结合了研究方法中的教学培训，与基本研究人员的积极合作以及杜克临床研究所独特研究环境中持续的临床研究经验。与精心选择的合作者一起，该职业发展计划将促进Felker博士的发展成为一个既定的独立临床研究者，具有复杂的临床研究方法论和炎症在心力衰竭病理生理学中的作用方面具有专业知识。